Gyre Therapeutics, Inc. (GYRE)
4.21
-0.31
(-6.86%)
USD |
NASDAQ |
Nov 20, 16:00
4.21
0.00 (0.00%)
After-Hours: 20:00
Gyre Therapeutics Enterprise Value : 441.84M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 441.84M |
| November 19, 2026 | 475.03M |
| November 18, 2026 | 455.76M |
| November 17, 2026 | 479.31M |
| November 16, 2026 | 461.11M |
| November 13, 2026 | 452.55M |
| November 12, 2026 | 451.48M |
| November 11, 2026 | 447.19M |
| November 10, 2026 | 443.98M |
| November 09, 2026 | 488.95M |
| November 06, 2026 | 500.73M |
| November 05, 2026 | 420.43M |
| November 04, 2026 | 466.46M |
| November 03, 2026 | 466.46M |
| November 02, 2026 | 497.51M |
| October 30, 2026 | 478.78M |
| October 29, 2026 | 677.39M |
| October 28, 2026 | 750.20M |
| October 27, 2026 | 690.24M |
| October 26, 2026 | 640.99M |
| October 23, 2026 | 617.43M |
| October 22, 2026 | 618.50M |
| October 21, 2026 | 622.78M |
| October 20, 2026 | 651.69M |
| October 19, 2026 | 643.13M |
| Date | Value |
|---|---|
| October 16, 2026 | 642.06M |
| October 15, 2026 | 676.32M |
| October 14, 2026 | 683.81M |
| October 13, 2026 | 709.51M |
| October 12, 2026 | 726.11M |
| October 09, 2026 | 744.84M |
| October 08, 2026 | 714.86M |
| October 07, 2026 | 744.84M |
| October 06, 2026 | 749.13M |
| October 05, 2026 | 778.03M |
| October 02, 2026 | 752.34M |
| October 01, 2026 | 740.56M |
| September 30, 2026 | 775.89M |
| September 29, 2026 | 761.78M |
| September 28, 2026 | 779.81M |
| September 25, 2026 | 764.96M |
| September 24, 2026 | 762.84M |
| September 23, 2026 | 770.26M |
| September 22, 2026 | 779.81M |
| September 21, 2026 | 773.44M |
| September 18, 2026 | 786.17M |
| September 17, 2026 | 746.94M |
| September 16, 2026 | 696.04M |
| September 15, 2026 | 694.98M |
| September 14, 2026 | 694.98M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Incyte Corp. | 19.57B |
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.478M |
| Revenue (Quarterly) | 32.93M |
| Total Expenses (Quarterly) | 36.99M |
| EPS Diluted (Quarterly) | -0.0381 |
| Gross Profit Margin (Quarterly) | 94.09% |
| Profit Margin (Quarterly) | -7.52% |
| Earnings Yield | -6.39% |
| Normalized Earnings Yield | -5.872 |